MedTech Innovator

Samay is a developer of an AI-enabled wearable device focused on remote respiratory health management, specifically targeting chronic obstructive pulmonary disease (COPD). The company's innovative chest patches utilize patented technology to diagnose COPD with 90% accuracy and identify exacerbation biomarkers at 83% accuracy, all while allowing patients to remain at home. The device continuously monitors various respiratory metrics, including pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, and temperature for up to two weeks. This real-time data collection empowers users to analyze their respiratory health and receive actionable insights to enhance their day-to-day well-being. Additionally, Samay is creating an AI-assisted management and diagnostic platform that supports both patients and doctors throughout the care continuum, from detecting exacerbations to determining effective therapies for more personalized treatment.

APrevent Medical Inc. is a medical device company based in Taipei, Taiwan, with an additional office in Austria. Founded in 2014, the company specializes in developing therapeutic devices aimed at enhancing the quality of life for patients affected by speech disorders. APrevent focuses on creating long-term implant systems and a speech conversion platform, along with other innovative medical equipment. Their offerings include minimally invasive ENT implants and Software-as-a-Service technologies designed to assist in the treatment of voice and communication disorders, enabling patients to improve their speech capabilities effectively.

Aurie is a medical device company based in New York, established in 2018. It focuses on developing a reusable urinary catheterization system aimed at improving the quality of life for individuals with disabilities. By providing a convenient, discreet, and hygienic catheterization option, Aurie seeks to reduce the risk of infections and enhance users' confidence and control over their healthcare needs. The company's innovative approach empowers users to manage their condition more effectively, enabling them to lead active and fulfilling lives.

INOPASE is a medical device company focused on the development of wirelessly powered, closed-loop implantable neuromodulation technologies. The company is currently advancing two key products: a closed-loop sacral neuromodulation system aimed at treating overactive bladder and a closed-loop brain neuromodulation device designed for epilepsy management. INOPASE's platform utilizes advanced algorithms to deliver personalized treatment plans by detecting symptoms and providing targeted stimulation therapy, positioning the company as a significant player in the treatment of chronic neurological diseases.

SmartCardia SA is a Swiss company established in 2013, specializing in the design and development of cardiac monitoring devices and cloud-based artificial intelligence software. The company offers a comprehensive platform for real-time patient monitoring, integrating advanced wearable technology with machine learning capabilities. Their flagship product, powered by SmartNeuralNet, enables continuous tracking of vital health indicators such as heart rate, breathing rate, and skin conductance. This innovative approach aims to provide patients with chronic conditions actionable insights into their health, facilitating better management of their medical needs. By leveraging deep learning and remote monitoring, SmartCardia aims to enhance the quality of life for patients while ensuring that healthcare providers have access to critical data for informed decision-making.

Surgical Automations focuses on the development of surgical robots and automation technologies aimed at improving patient safety and reducing medical errors. Their offerings include an AI-driven autonomous robotic navigation system tailored for endoscopic diagnostic and interventional procedures. A key innovation is their automated endotracheal intubation system, which accurately identifies the trachea's opening and facilitates the insertion of the endotracheal tube. This technology is designed to enhance surgical precision and minimize risks during medical procedures.

Craif Inc., previously known as Icaria Inc., is a Tokyo-based company founded in 2018 that specializes in developing innovative devices for early cancer detection through urine tests. The company's flagship product is a MicroRNA device that serves as a biomarker for identifying early-stage cancers. Craif aims to revolutionize cancer diagnosis by providing a method that is painless, accurate, and suitable for regular screening, addressing the critical need for early detection in order to significantly improve survival rates. Traditional cancer diagnostic methods often involve discomfort and lack the precision required for early-stage identification, which can lead to late-stage diagnoses when treatment options are limited. Craif's technology leverages exosome-based liquid biopsy tests that analyze ribonucleic acid, allowing for high sensitivity and specificity in distinguishing cancerous from non-cancerous samples.

Nanochon is focused on creating innovative implantable medical devices designed to address cartilage damage in joints. Utilizing advanced 3D printing techniques and a unique nanomaterial, the company aims to develop solutions that not only replace lost and damaged cartilage but also promote the growth of new tissue. This approach allows medical practitioners to access cost-effective and on-demand devices that enhance treatment outcomes, particularly for young and active patients suffering from knee injuries and diseases. Through its technology, Nanochon seeks to improve the overall quality of care in orthopedics.

X-BOLT Orthopaedics developed a novel expanding bolt device, with associated implants and instrumentation systems, for internal bone fixation in osteoporotic hip fractures. X-BOLT hip plating and nailing systems allow surgeons choice to treat all morphologies of proximal femoral fractures.

Niramai Health Analytix Private Limited is a Bengaluru-based company founded in 2016 that specializes in cancer screening solutions. Its primary product, Thermalytix, is a software that utilizes machine intelligence to analyze thermography images, enabling early detection of breast cancer. This innovative approach allows for the identification of tumors significantly smaller than those detectable by traditional methods, making it a critical tool for improving survival rates. Niramai’s offerings include a compact screening device for specialty hospitals, a handheld device for independent medical practitioners with real-time cloud-based diagnostics, and a portable solution suitable for large-scale screenings. The technology is designed to be cost-effective, non-invasive, painless, and free of radiation, allowing women across all age groups to undergo frequent screenings with minimal human supervision and side effects.

Samay is a developer of an AI-enabled wearable device focused on remote respiratory health management, specifically targeting chronic obstructive pulmonary disease (COPD). The company's innovative chest patches utilize patented technology to diagnose COPD with 90% accuracy and identify exacerbation biomarkers at 83% accuracy, all while allowing patients to remain at home. The device continuously monitors various respiratory metrics, including pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, and temperature for up to two weeks. This real-time data collection empowers users to analyze their respiratory health and receive actionable insights to enhance their day-to-day well-being. Additionally, Samay is creating an AI-assisted management and diagnostic platform that supports both patients and doctors throughout the care continuum, from detecting exacerbations to determining effective therapies for more personalized treatment.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

Ligence is a Deep Tech startup based in Lithuania, specializing in healthcare solutions developed by a team of medical doctors proficient in artificial intelligence. The company focuses on automating heart ultrasound image analysis through its flagship product, Ligence Heart. This technology employs deep learning algorithms to accurately recognize various heart image views and perform essential measurements automatically. By streamlining the analysis process, Ligence Heart allows physicians to bypass manual measurements, enabling cardiologists and sonographers to enhance efficiency and significantly reduce analysis time, thereby allowing them to concentrate more on patient care and treatment.

Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.

Swift Duct develops a navigational tool for the ERCP procedure, which minimizes the risk of infections in the pancreas.

myBiometry is developing a platform to monitor/manage patients with chronic disease using biomarker data from proprietary sensors and ML to identify patients at risk of treatment failure. Our initial focus is asthma where treatment failure occurs over 46% of the time (11.5M US patients, $80 billion). We are developing a single use, disposable sensor and device to track a biomarker of inflammation in breath. The data determines changes in adherence, treatment response, and risk of attack.

Invicta Medical is a medical technology company focused on developing innovative treatments for sleep apnea and snoring. Founded in 2013 and based in California, the company has created a wearable neurostimulation device that detects and treats disturbed breathing through electrical stimulation. This device aims to overcome the limitations of traditional therapies, which are often expensive, intrusive, and associated with low patient compliance rates. By providing a smart, comfortable, and cost-effective solution, Invicta Medical seeks to enhance the effectiveness of treatment for sleep disorders and improve patient outcomes.

REMEDI is a solution provider for radiotherapy and radiography.

Nanobiofab, founded in 2015 and based in Frederick, Maryland, specializes in the development of wearable, smart healthcare and medical devices utilizing nanotechnology for both humans and pets. The company is known for its product, iNose, which enables users to detect, track, and monitor their body's skin vapor-print. This device wirelessly connects to mobile phones to help individuals assess their fat burning rate and evaluate the effectiveness of their exercise routines. Additionally, it provides insights into the effects of dietary choices over time and tracks metabolic rates. Beyond consumer products, Nanobiofab also offers technology and services aimed at accelerating nanomaterial research and development, including nanoprinting solutions and artificial intelligence sensors for telemedicine and personalized healthcare applications.

Solenic Medical, Inc. is a medical device company founded in 2019 and based in College Station, Texas. It specializes in developing a non-invasive treatment for infected metallic implants using a technology that employs alternating magnetic fields generated by external coils. This innovative approach targets biofilm on the surfaces of medical implants, which is a significant complication in surgeries like knee and hip replacements, as well as in trauma-related procedures involving plates and rods. The technology has the potential to replace the costly and risky two-step revision surgical procedure currently used to address chronic infections in medical implants, thereby offering a safer and more effective solution for patients.

Butterfly Medical Ltd is a medical device company based in Yokne'am, Israel, founded in 2014. The company specializes in developing an innovative implantable device designed to treat Benign Prostatic Hyperplasia (BPH), commonly known as enlarged prostate. This device offers a fast, simple, and minimally invasive alternative to conventional BPH treatments, such as medication and surgery. It can be placed in under ten minutes in an office setting, using local anesthesia and without the need for surgical incisions or tissue removal. This approach aims to provide a long-term solution with minimal side effects, eliminating the need for hospitalization or general anesthesia. Early clinical trials have shown promising results, with effective outcomes in relieving blocked urethras and no reported side effects. Butterfly Medical is advancing further clinical studies at leading medical centers in Europe to validate its device's efficacy and safety.

EndoVision Limited, founded in 2018 and based in Hong Kong, specializes in the development of artificial intelligence software designed for computer-aided diagnosis in endoscopy. The company's innovative technology aims to enhance the accuracy and efficiency of medical diagnoses during endoscopic procedures, providing healthcare professionals with advanced tools to improve patient outcomes.

Ortho-tag specializes in developing innovative technologies that facilitate wireless communication between digital health applications and implanted medical devices. Their in-vivo platform enables real-time data exchange and in-body communication through a proprietary method known as transcutaneous volume conduction. This technology enhances the functionality of smart medical implants by allowing for efficient powering, data storage, and nano diagnostic capabilities. By bridging the gap between digital health technologies and the human body, Ortho-tag aims to improve the integration and performance of medical devices, thereby enhancing patient care and monitoring.

DiaMonTech AG is a medical technology company based in Berlin, Germany, focused on developing non-invasive diagnostic devices for blood glucose monitoring. Founded in 2015, the company utilizes a proprietary laser-based photo-thermal detection technology to measure glucose levels without the need for blood draws or finger pricking, thereby offering a painless alternative for diabetes management. DiaMonTech's product lineup includes the D-BASE, a device designed for human trials, the D-pocket, a compact personal device for frequent glucose tracking, and the D-BAND, a wearable device that continuously monitors blood sugar levels. Through its innovative solutions, DiaMonTech aims to enhance the quality of life for individuals managing diabetes.

iCE Neurosystems develops a neuromonitoring platform that focuses on providing early warnings and guiding treatment for patients with brain injuries. By integrating innovative devices, advanced software, and big-data methodologies, the company offers healthcare professionals real-time insights into brain health. This approach allows doctors and nurses to diagnose and prevent brain injuries in critically ill patients, enhancing their ability to deliver timely and effective care.

Progressive Neuro, Inc is a Silicon Prairie Center incubated medical device company dedicated to the development of Progressive Stroke Solutions. Progressive Neuro, Inc is focused on developing a unique portfolio of ischemic stroke devices that provide physicians with treatment options beyond aspiration and traditional thrombectomy.

TYBR Health is a medical device company based in Houston, Texas, founded in 2020 by Tim Keane and Alex Smith. The company focuses on developing a sprayable hydrogel designed to protect healing tissues and minimize internal scarring, a common complication following surgical procedures. This innovative hydrogel solution is delivered through a user-friendly device, making it suitable for both open and minimally invasive surgeries. By reducing scarring by 75% in preclinical studies, TYBR's product aims to enhance recovery and improve the healing response of tissues, ultimately benefiting patients who have undergone operations that risk damaging vital internal organs.

ATDev specializes in assistive technology and medical device solutions, focusing on the development of innovative mobility devices. These devices are designed to enhance physical therapy accessibility for patients in the United States and globally. By integrating robotics into their solutions, ATDev aims to transform traditional physical therapy practices, facilitating improved patient outcomes and enabling healthcare providers to overcome challenges related to care delivery. Their technology specifically addresses the needs of individuals recovering from knee surgery, thereby enhancing the quality of care and support during rehabilitation.

Promedius, established in 2019, focuses on transforming the approach to aging by developing innovative solutions for the early detection and management of musculoskeletal and metabolic diseases, particularly osteoporosis. The company aims to improve the quality of life and extend healthy lifespans through advanced technology. Its flagship product, PROS® CXR:OSTEO, is a pioneering screening solution that utilizes chest X-ray images to identify individuals at risk of osteoporosis. By employing artificial intelligence in medical imaging, Promedius provides medical professionals with efficient tools to prevent severe fractures among the elderly population, thereby contributing to better health outcomes and enhancing patient care.

Dopl Technologies, co-founded by an ex-Microsoft engineer and two Harvard-trained experts, focuses on enhancing healthcare access for underserved populations, particularly in rural areas where healthcare resources are limited. The company has developed a telerobotic ultrasound system that allows specialists to conduct diagnostic ultrasound procedures remotely, addressing the issue of specialists being predominantly located in urban centers. This innovative platform aims to improve patient access to timely care, enhance health outcomes, and provide financial benefits to hospitals by reducing costs and increasing revenue. By leveraging technology, Dopl seeks to bridge the gap in healthcare availability and ensure that quality medical services reach those who need them most.

CytoVeris is a company focused on developing optical-based technologies to assist surgical oncologists in identifying and removing tumor tissue during cancer resection surgeries. Founded in 2018 by Alan Kersey in Farmington, Connecticut, CytoVeris aims to enhance the surgeon's ability to achieve clean margins, thereby improving patient outcomes. The company’s devices facilitate real-time assessment of tissue and generate molecular-specific information by detecting unique signatures created by cancer cells that alter cellular metabolic processes. This includes variations in lipids, proteins, and metabolites, which can be identified using their OncoMap system. By providing oncologists with critical information during surgery, CytoVeris seeks to reduce healthcare costs associated with repeat surgeries.

FemTherapeutics Inc. is a Montreal-based medical device company focused on personalizing therapeutics in women's health. The company has developed an artificial intelligence platform that utilizes patient data to create innovative medical devices, specifically customizable gynecological prosthetics designed to enhance the management of Pelvic Floor Disorders. Their initial product line features patient-specific vaginal pessaries, which aim to provide effective symptomatic relief for conditions such as pelvic organ prolapse and stress urinary incontinence. By employing advanced technologies like three-dimensional printing, FemTherapeutics seeks to improve clinical outcomes and restore quality of life for women facing these health challenges.

INIA Biosciences focuses on creating non-invasive medical devices that leverage sound wave technology to manage chronic inflammatory diseases. The company's innovative system combines biomarker monitoring with an ultrasound stimulator, aimed at reducing inflammation associated with transplant rejection and decreasing reliance on immunosuppressant medications. This home-administered, closed-loop monitoring system provides physicians with advanced diagnostic capabilities to improve the treatment and prevention of organ failure, ultimately enhancing patient care in chronic disease management.

Fasciotens GmbH is a medical technology company based in Essen, Germany, founded in 2016. The company specializes in developing innovative devices for open abdomen therapy, which is crucial in treating severe infections, postoperative complications, and injuries that necessitate leaving the abdomen open. This therapy can be life-saving, particularly in cases such as abdominal compartment syndrome. Fasciotens' approach involves a unique method that maintains tension in the abdominal wall while increasing intra-abdominal volume. This technique combines the principles of mesh-mediated traction with those of an external fixator, ultimately enhancing the likelihood of successful outcomes for critically ill patients. Through its advanced solutions, Fasciotens aims to improve medical care in challenging surgical situations involving the open abdomen.

Flow Medical specializes in the development of advanced multi-function catheters aimed at diagnosing and treating venous thromboembolic conditions, including pulmonary embolism. Their innovative platform enhances clot visualization and allows for the direct delivery of clot-dissolving medication to the blockage. Additionally, it enables real-time monitoring of treatment progress, empowering clinicians to tailor therapies to individual patient needs effectively. This approach positions Flow Medical as a key player in improving patient outcomes in the management of thromboembolic illnesses.

Nanotis Corporation, founded in 2016 and based in Tokyo, Japan, specializes in the development of instant diagnostic devices, particularly for infectious diseases such as influenza. The company manufactures microchip devices that allow users to achieve rapid and accurate diagnoses, which are essential for medical professionals in practical healthcare settings. By providing timely information, Nanotis aims to enhance the efficiency of healthcare delivery and assist individuals facing health challenges.

Juniper Biomedical is a medical device company focused on implantable neuromodulation technology aimed at improving pelvic health. The company has developed a micro-implant that provides precision treatment for various pelvic health conditions by modulating distal target nerves locally. This technology specifically stimulates only the target nerves, allowing for less invasive and safer therapeutic options. It addresses a range of issues, including incontinence, sexual dysfunction, and chronic pain, offering patients more effective solutions for managing their health concerns.

Neurovalens Limited specializes in the development of non-invasive neurostimulation medical devices aimed at addressing global health challenges such as obesity. Founded in 2013 and headquartered in Ballymena, United Kingdom, the company offers products like Stimu Slim and Modius, which are electronic headsets designed to influence brain activity and support weight management. Neurovalens employs advanced technologies to activate specific brain regions, enabling adjustments in autonomic function and neuro-metabolic processes. The company has received funding from Invest NI as part of the European Union’s Investment for Growth and Jobs Programme to support its research and development initiatives, enhancing its competitiveness in the field of neuroscience and bioscience.

StrokeDx specializes in creating innovative and portable diagnostic devices aimed at improving stroke care. The company leverages advanced machine learning and artificial intelligence to enhance the diagnostic accuracy and imaging capabilities of its microsensors. These devices are designed to detect blood in the brain and generate predictive images of stroke locations, allowing for rapid triage and diagnosis. By offering a cost-effective alternative to traditional methods, StrokeDx aims to reduce the time to treatment, ultimately improving patient outcomes in emergency situations.

Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.

Fingy3D is a company focused on making prosthetic devices accessible to individuals, specifically targeting finger prosthetics. Utilizing an AI scanner, the company accurately measures the user's finger dimensions and generates a custom prosthetic that is 3D printed. This innovative approach allows customers to receive personalized finger prosthetics conveniently at their doorsteps, ensuring that even the smallest digit can be replaced and made functional. Fingy3D aims to enhance the quality of life for those in need of prosthetic solutions.

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.

Perceptive Medical is a developer of medical devices focused on enhancing blood pressure management in critical care settings, specifically in intensive care units (ICUs) and operating rooms. The company's products are designed to integrate seamlessly into modern clinical workflows, providing precision in therapy and addressing inefficiencies in blood pressure management. By enabling measurable improvements in patient care, Perceptive Medical aims to support clinical providers in delivering better outcomes for patients undergoing critical treatment.

AMI Co., Ltd, established in 2015 and headquartered in Minamata-shi, Japan, specializes in manufacturing medical equipment, notably stethoscopes. The company also offers healthcare consulting services, including hospital management and clinical research. AMI Corp's core business involves medical consulting and the development of medical devices, with a focus on telehealth solutions. It operates a telemedicine system centered around a stethoscope and has developed a video chat system for remote auscultation, enabling patients to access medical services remotely.

Senseye, Inc. is a company based in Los Angeles, California, focused on developing smart contact lenses that non-invasively gather data from users. Founded in 2015, the company aims to infer human emotions, thoughts, and health states to support various applications in market research, disease diagnosis, and early detection of conditions such as strokes and heart attacks. By utilizing innovative measurements of ocular physiology, Senseye quantifies cognitive abilities, health metrics, and psychological well-being, including vital signs and cognitive load. The platform is designed to enhance clinicians' ability to provide personalized care, allowing them to establish baselines and monitor patient outcomes effectively. As the technology advances, Senseye intends to place greater emphasis on emotional responses and mental health diagnostics, offering new insights into cognitive and health parameters through standard camera equipment.

Covellus is a medical device company focused on developing innovative catheter technologies for minimally invasive surgeries. It specializes in manufacturing vascular catheters and modular catheter systems that allow physicians to customize devices according to individual patient needs. By offering a unique platform technology, Covellus aims to enhance the effectiveness and personalization of medical treatments through its advanced product offerings.

MACH32 is a medical device company focused on developing innovative drug delivery solutions to address significant healthcare challenges. The company specializes in creating medical devices designed for the pre-hospital treatment of trauma, producing reliable and functional tools that aim to save lives in urgent situations. Their technology includes novel drug-delivery systems that enable healthcare professionals to utilize protective equipment effectively, safeguarding them from infectious aerosols, particularly highlighted during the Covid-19 pandemic. By prioritizing safety and efficacy, MACH32 addresses critical needs in emergency medical care.

Sentante is a medical device company focused on developing robotic teleoperated systems specifically for endovascular procedures. By utilizing this innovative technology, Sentante enables physicians to perform surgeries remotely, significantly reducing their exposure to harmful X-rays. The company has designed a manipulator that assists endovascular practitioners in conducting procedures with minimal radiation risk, promoting safer practices in the medical field. Additionally, Sentante's robotic systems facilitate minimally invasive coronary procedures, enhancing the ability of surgeons to carry out complex endovascular surgeries while also contributing to a decrease in oncological diseases among healthcare personnel.

Vitestro is a company focused on enhancing patient care through innovative autonomous blood drawing technology. It develops medical robotic devices tailored for use in hospitals and clinical laboratories. The company’s key product utilizes multi-dimensional ultrasound to detect nerves and arteries, leveraging deep learning to minimize the risk of arterial complications during blood draws. This advanced technology not only aids healthcare professionals in performing procedures with greater precision but also aims to improve overall patient health outcomes by reducing complications associated with traditional blood collection methods.

Happitech is a pioneering company that offers a CE Certified heart rate software development kit (SDK) for Android and iOS, facilitating remote patient management through mobile applications. By integrating Happitech's algorithms, users can monitor vital signs, including heart rate and heart rate variability, utilizing only a smartphone camera. The technology is backed by clinical evidence and powered by AI, making it suitable for various applications such as cardiovascular screening, stroke prevention, and telehealth services. Happitech's solutions are designed to enhance care management, support health practitioners, and empower patients globally. The company has received multiple accolades, including recognition as one of the top Dutch COVID-19 healthcare companies and awards for its innovative contributions to digital health.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Pumpinheart is a medical device company specializing in the development of an implantable left ventricular assist device (LVAD) for the treatment of heart failure with preserved ejection fraction (HFpEF). Their device, an electromedical pump, is designed to reduce left atrial pressure during diastole, improving heart function and potentially reducing hospitalizations. The pump is implanted in the left ventricle and operates in sync with the heart's natural rhythm, providing a minimally invasive treatment option for patients with HFpEF.

Xtremedy Medical, based at NUI Galway, specializes in manufacturing innovative surgical devices. These devices use electrical signals to treat bone and deep tissue infections, including diabetic foot ulcers. By targeting both surface and underlying infections, the company's technology helps doctors enhance treatment outcomes, reducing the risk of amputations and promoting faster patient recovery.

Prana Thoracic, Inc. is a Houston-based medical device startup focused on addressing the challenges of early intervention in lung cancer, which remains a leading cause of cancer-related deaths in the United States. The company aims to enhance screening and diagnosis by developing advanced surgical tools that facilitate the capture and analysis of small, suspicious lung nodules. Their innovative device employs a tissue-sparing electrosurgical technique that utilizes bipolar radiofrequency energy, allowing for simultaneous cutting and sealing. This approach minimizes the risk of complications associated with traditional methods, thereby improving the prospects for early detection and treatment. By providing physicians with more effective tools, Prana Thoracic seeks to revolutionize the management of lung cancer, ensuring that patients receive timely interventions and improving overall survival rates.

Adcura, Inc. is a medical device company specializing in minimally invasive implant products aimed at enhancing the quality of life for patients with spine-related conditions. The company develops a range of innovative products, including retractors, disposable accessories, and adjustable lumbar fusion devices, which are designed to address existing surgical inefficiencies. By focusing on precision technologies and surgical techniques, Adcura enables medical practitioners to improve surgical outcomes while reducing post-operative complications for patients.

VeinWay is a medical device company focused on developing innovative solutions for chronic venous occlusions caused by blockages or disease. The firm has created a specialized catheter designed to assist physicians in recanalizing obstructed veins, facilitating the restoration of blood flow to the heart. This platform provides a dedicated tool that enables medical professionals to navigate complex blockages that were previously deemed uncrossable, thereby improving the efficiency and safety of venous treatments. By addressing the challenges associated with chronic venous disease, VeinWay aims to transform the approach to treating these conditions.

Sparta Biomedical develops cartilage-like implants for the knee. They specialise in the creation of biomimetic implants that require minimally invasive therapy for chondral or osteochondral knee cartilage abnormalities, providing orthopaedic surgeons with enhancements that fundamentally restore movement for their patients.

JuneBrain, LLC is a Washington, D.C.-based company founded in 2017 that focuses on developing wearable and non-invasive imaging devices for multiple sclerosis patients. The technology allows patients to monitor their disease activity from home, facilitating earlier detection of MS attacks and enhancing the monitoring of treatment efficacy. By leveraging telemedicine, JuneBrain aims to optimize remote assessment for neurological diseases, thereby enabling clinicians to track patients outside traditional clinical settings. The company's long-term vision includes extending its device's applications to a broader range of neurodegenerative diseases, promoting more accessible and frequent monitoring of brain health.

Thermidas, a Finnish health technology company, specializes in developing and advancing infrared thermal imaging for diagnostic purposes. Its core product is thermal imaging software, designed to support screening, early diagnostics, and evaluation of treatment effectiveness. The technology enables swift and simple detection of asymmetric body temperature, which can indicate underlying health issues like inflammation, circulatory problems, and potential ulcers. This allows university hospitals and experienced clinicians to identify and diagnose conditions earlier than traditional methods.

Sonavi Labs, Inc. is a Baltimore-based company that specializes in the development of medical devices and artificial intelligence-based software aimed at respiratory monitoring and diagnostic support. Founded in 2017, the company focuses on creating innovative products that analyze body sounds to assist in the diagnosis of respiratory diseases. By leveraging advanced technology, Sonavi Labs enables healthcare providers to detect, monitor, and potentially predict respiratory conditions by identifying abnormalities in the sounds produced by the body. This approach enhances the capabilities of medical professionals and aims to improve the patient experience in managing respiratory health.

Opticyte, Inc. is a medical device company based in Seattle, WA, focused on developing innovative technology for monitoring oxygen levels in cells to prevent organ failure. Founded in 2016 as a spinoff from the University of Washington, Opticyte is creating the first Cell O2 Monitor, a noninvasive oximeter that utilizes advanced algorithms and optical spectroscopy. This device is designed to measure oxygen concentration within cells, facilitating early detection of critical conditions such as shock, sepsis, hemorrhage, and cardiac dysfunction. By enabling clinicians to make timely treatment decisions, Opticyte aims to reduce the risk of multiple organ failure and improve patient outcomes. The company comprises a team with significant expertise in engineering, regulatory affairs, and communications, dedicated to bringing this essential medical technology to market.

Xcision Medical Systems, LLC is a medical technology company focused on developing advanced stereotactic radiotherapy solutions, particularly for breast cancer treatment. The company's innovative device utilizes stereotactic gamma irradiation, allowing patients to complete their radiation therapy in a single, noninvasive session, rather than over several weeks. This approach not only significantly reduces the duration of treatment but also minimizes radiation exposure to surrounding healthy tissues, including the lungs and heart. By enhancing the quality of cancer care, Xcision aims to improve patient outcomes and enable individuals to return to their daily lives more quickly and with less discomfort.

Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.

Averto Medical is a manufacturer of medical devices focused on addressing gastrointestinal diseases. The company specializes in developing innovative solutions designed to facilitate minimally invasive colorectal tumor removal, which aims to reduce the need for multiple surgical procedures and associated complications. By providing effective medical care options for patients suffering from gastrointestinal disorders, Averto Medical seeks to improve patient outcomes and streamline treatment processes in this critical area of healthcare.

Endocision is focused on creating innovative minimally-invasive medical devices aimed at enhancing the diagnosis and treatment of lung diseases. The company specializes in technologies compatible with bronchoscopy and robotic bronchoscopy, offering solutions that include a cryo-biopsy platform. These advancements enable healthcare professionals to effectively diagnose and manage conditions such as interstitial lung disease and lung cancer. By prioritizing safety and efficacy, Endocision seeks to improve patient outcomes in the field of pulmonary medicine.

Total Flow Medical is a medical device startup focused on enhancing the quality of life for patients undergoing cardiac surgery and life support. The company is developing innovative medical devices aimed at preventing injuries in patients who require extracorporeal circulation. Its initial product is a user-friendly cannula designed for minimally invasive cardiopulmonary bypass surgery, which helps reduce the risks of injury and death associated with traditional invasive procedures.

Mirai Medical is a medical device company focused on developing innovative technologies for cancer therapy. Its unique intellectual property allows for the painless delivery of electroporation energy through endoscopic procedures, significantly improving the treatment of cancer. This technology enables endoscopists to perform pulse field ablation safely and efficiently, ultimately aiming to enhance patient outcomes and experiences in cancer treatment.

StrokeDx specializes in creating innovative and portable diagnostic devices aimed at improving stroke care. The company leverages advanced machine learning and artificial intelligence to enhance the diagnostic accuracy and imaging capabilities of its microsensors. These devices are designed to detect blood in the brain and generate predictive images of stroke locations, allowing for rapid triage and diagnosis. By offering a cost-effective alternative to traditional methods, StrokeDx aims to reduce the time to treatment, ultimately improving patient outcomes in emergency situations.

Fingy3D is a company focused on making prosthetic devices accessible to individuals, specifically targeting finger prosthetics. Utilizing an AI scanner, the company accurately measures the user's finger dimensions and generates a custom prosthetic that is 3D printed. This innovative approach allows customers to receive personalized finger prosthetics conveniently at their doorsteps, ensuring that even the smallest digit can be replaced and made functional. Fingy3D aims to enhance the quality of life for those in need of prosthetic solutions.

Purgo Scientific is a medical device company focused on developing an innovative drug delivery system aimed at addressing the challenges posed by biofilm infections in orthopedic surgery. The company's technology is designed to create a sustainable, localized delivery method that targets therapeutic drugs directly to the site of infection, thereby treating and preventing biofilm-related surgical site infections that can affect orthopedic implants. This approach not only aims to eradicate infections caused by biofilms but also has potential applications in managing various health issues that benefit from precise medicine delivery, including pain management and oncology.

ImmersiveTouch, Inc. is a medical technology company based in Chicago, Illinois, specializing in virtual reality simulators for medical training and patient engagement. Established in 2005, the company develops applications for surgical education and pre-operative planning, utilizing its advanced Ikshana XR platform. This platform employs proprietary software and artificial intelligence to convert radiology scans into 3D simulations, allowing for detailed anatomical exploration and informed surgical decision-making. ImmersiveTouch's surgical simulators feature an immersive pod where surgeons interact with realistic 3D models, experiencing high visual acuity and realistic sensory feedback. The training modules cover various specialties, including core surgical skills, neurosurgery, orthopedic surgery, spine, and ophthalmology. By providing actionable insights, ImmersiveTouch aims to improve patient outcomes, reduce complications, and enhance the efficiency of surgical procedures.

CORIT Medical LLC is a medical device company based in McLean, VA, specializing in a Class I single-use surgical device designed to enhance breathing. Their patented device is specifically aimed at improving the established Ear, Nose & Throat (ENT) procedure known as inferior turbinate reduction. With over 1 million procedures performed annually in the U.S. and more than 50 million individuals suffering from obstructed breathing, CORIT's hand-powered device offers an efficient solution, requiring no expensive setup or equipment. The device not only allows ENT specialists to perform the procedure quickly in their offices, but it also yields long-lasting results compared to existing technologies, which may revert to pre-treatment obstruction levels within six months. This combination of efficiency and effectiveness has generated significant interest among ENTs, who are eager to adopt the device due to its potential for higher reimbursement rates and improved patient outcomes.

Medical Devices Corner is a company focused on developing innovative medical devices aimed at enhancing cancer diagnosis and treatment. Their primary offering is a novel robotic system designed to facilitate minimally invasive surgeries. By advancing device technology, the company supports healthcare professionals in performing procedures that include biopsies and ablations with reduced invasiveness. Through its commitment to improving surgical techniques, Medical Devices Corner plays a crucial role in the health industry, striving to enhance patient outcomes and streamline medical processes.

Manufacturers of innovative medical devices intended to incorporate sensors, both therapeutic and diagnostic, to help people overcome musculoskeletal problems. The company provides NMES (Neuromuscular Electrical Stimulation) devices that invoke neuroplasticity for optimal outcomes and offers medical devices for physical therapy and rehabilitation, thereby enabling patients to regain and improve their range of motion and function.

3EO Health is focused on creating a society where individuals can take charge of their health, benefiting themselves, their families, and their communities. The company develops innovative molecular point-of-care platforms that utilize advanced technology to significantly reduce costs while enhancing access to impactful diagnostic tools. By offering 3TR technology, 3EO Health ensures that both physicians and consumers have equitable access to affordable and user-friendly health solutions. This approach aims to extend healthcare beyond traditional settings into communities, workplaces, and homes, empowering people to thrive and optimize their health effectively.

270Surgical Ltd. is a medical device company based in Netanya, Israel, founded in 2016. It specializes in the development of the SurroundScope System, an innovative laparoscopic camera designed to enhance visualization during surgery. This system features a unique 270-degree wide field of view technology, which significantly reduces blind spots and the risk of off-screen injuries, thereby improving patient outcomes. The SurroundScope also addresses common issues faced during laparoscopic procedures, such as lens fogging and visual obstructions from surgical smoke. The system has received FDA clearance and has garnered endorsements from leading experts in the field, positioning 270Surgical as a key player in advancing surgical techniques.

CerebraAI is a digital diagnostic company focused on improving stroke diagnosis through advanced artificial intelligence technology. Since its inception in 2018, the company has developed CEREBRA, an AI-powered software that enhances the efficiency of CT machines. This software enables rapid detection of acute ischemic stroke within five minutes using non-contrast computed tomography, facilitating quicker and more accurate treatment for patients. By empowering community hospitals with these innovative tools, CerebraAI aims to optimize patient outcomes in neuroradiology and address the critical time sensitivity associated with stroke care.

Healthcare is moving to the outpatient setting to save costs, but at home patients struggle with medication adherence and they are readmitted at alarming rates. Hospitals send 1.4 million patients home for 4-6 weeks to administer their own IV antibiotics every year. Twenty percent of patients on outpatient parenteral antimicrobial therapy (OPAT) are readmitted, each costing $80,000 on average. This is a $22.4 billion problem. Clinicians at the 12,200 home infusion providers in the US have no objective way to identify non-adherence to intervene and prevent readmissions. Rather, they call patients to detect non-adherence, which is time-consuming, inaccurate, and prone to reporting bias. They need a better tool than a phone to monitor adherence. The solution is HIVE’s patent pending CloudConnect smart catheter. CloudConnect is a reinvented IV line with a simple embedded mechanoelectrical sensor that detects when a medication source is connected. CloudConnect wirelessly sends this information to electronic medical records. HIVE’s value proposition is that clinicians can detect non-adherence in real time and make treatment decisions and prevent costly readmissions based on objective data. HIVE offers CloudConnect as an alternative to the need for clinicians to call every patient with standard IV lines.

EchoPixel, Inc. is a company that specializes in 3D medical visualization software, providing tools for medical professionals to interact with patient-specific organs and tissues in an immersive environment. Its flagship product, the True 3D Viewer, is a real-time interactive virtual reality system that enhances the ability of doctors to identify, evaluate, and dissect anatomical structures. Additionally, the True 3D Medical Education Viewer aids medical students in understanding structural 3D biology by utilizing computer tomography and magnetic resonance images. EchoPixel also offers a holographic intraoperative software that supports structural heart procedures through interactive 3D anatomical imaging. Founded in 2012 and based in Mountain View, California, the company aims to improve diagnostic and educational capabilities in the medical field through advanced imaging technology.

Plio Surgical is a company in the medical devices sector focused on developing innovative solutions for intestinal anastomosis procedures. The firm has created a device that is laparoscopically deployed into the healthy lumen of the bowel. Once the bowel heals, the device detaches and passes naturally, leaving no foreign material in the body. This technology aims to simplify the surgical process and enhance patient outcomes by addressing unmet clinical needs in gastrointestinal surgery.

NeuraStasis is focused on developing a non-invasive electrical neurostimulation method aimed at preventing strokes. The company has created a novel device that activates the body's natural oxygen-preserving and anti-inflammatory reflexes, which helps to preserve brain tissue during critical moments. This approach not only delays brain damage but also provides healthcare providers with additional time to intervene effectively. Ultimately, NeuraStasis seeks to empower patients to leave the hospital without disabilities following a stroke, enhancing recovery outcomes and improving quality of life.

Invenio Imaging, Inc. is a privately held company founded in 2012 and based in Santa Clara, California. The company specializes in developing advanced technology for non-destructive microscopic analysis of the molecular composition of tissues and materials. Its primary product is a multi-modal coherent Raman scattering microscope, which is designed for both research and high-value medical applications. This innovative imaging system facilitates intraoperative histology by providing high-resolution images that allow researchers to examine tissue specimens from multiple surgical sites. Invenio Imaging's technology is underpinned by research from Prof. Sunney Xie at Harvard University and has received funding from the National Science Foundation and the National Institutes of Health's Small Business Innovation Research programs.

EvoEndo specializes in developing innovative systems that facilitate unsedated endoscopic procedures for both pediatric and adult patients. The company combines sterile, single-use, multi-specialty flexible endoscopes with a virtual reality-based distraction method, allowing patients to undergo routine endoscopies without the need for general anesthesia or sedation. This approach not only reduces the complexity and cost of the procedures but also alleviates patient and provider apprehension. EvoEndo's comprehensive software integration platform further enhances the effectiveness of its technology, streamlining the endoscopic process and promoting a more comfortable experience for patients.

Discure Technologies is focused on creating a minimally invasive, implantable bioelectronic device aimed at treating degenerative disc disease (DDD). This innovative device employs a novel bioelectric technique that addresses the root cause of DDD, allowing physicians to alleviate pain and restore normal disc function in patients. By promoting healing of the affected discs, Discure seeks to improve the quality of life for individuals suffering from this condition.

CARI Health is a digital health company based in San Diego, California, that specializes in the development of remote medication monitors. Founded in 2015 and incorporated in 2021, the company creates wireless sensors that patients wear on their skin. These sensors continuously transmit real-time data about medication levels to the cloud, allowing clinicians to safely prescribe, dose, and monitor adherence to critical medications. By providing this innovative solution, CARI Health aims to enhance patient care and improve health outcomes through better medication management.

Leadoptik is a deep-tech company focused on developing advanced miniature imaging technology designed for minimally invasive medical procedures. Its platform enhances surgical capabilities by providing high-resolution imaging and 3D navigation in real time, allowing surgeons to visualize small anatomical structures with greater clarity than existing imaging systems. This innovative approach facilitates the early detection of cancer and improves the overall effectiveness of surgical interventions, ultimately contributing to better patient outcomes.

Liquet Medical is a medical device development company focused on improving the treatment of vascular disease through innovative localized drug delivery methods. The company's flagship product, the Versus Catheter, features a dual-tip infusion design, real-time pressure monitoring, and a flow-directed placement balloon. These advancements aim to enhance patient outcomes and promote healthcare sustainability by providing healthcare professionals with more effective tools for managing vascular conditions. Liquet Medical's commitment to developing patented technologies positions it as a significant player in the medical device sector.

Fluid Biomed is a medical device start-up dedicated to the development of an innovative implantable dissolving stent specifically designed for the treatment of brain aneurysms. Founded by a team of neurosurgeons, the company aims to enhance patient outcomes by offering a bio-absorbable polymer-based flow-diverting stent that promotes healing and minimizes the need for invasive surgical procedures. This revolutionary device gently redirects blood flow to facilitate the healing of weakened aneurysms, enabling physicians to treat patients efficiently and effectively while reducing the risk of complications such as stroke.

Gradient Denervation Technologies is a Paris-based company founded in 2019 that focuses on the development of an endovascular catheter-based medical device designed to treat pulmonary hypertension. This innovative technology aims to reduce pulmonary vascular resistance and enhance cardiovascular hemodynamics through a minimally invasive procedure. The device is built on prior research and intellectual property developed at Stanford University and offers a novel approach to pulmonary artery denervation, addressing heart failure and associated pulmonary hypertension. By providing a reliable and effective treatment option, the company seeks to improve patient outcomes in the healthcare industry.

Woven Orthopedic Technologies, LLC is a medical device company based in Manchester, Connecticut, specializing in the design and development of orthopedic technologies. Founded in 2013, the company focuses on enhancing the screw-to-bone interface to address the loss of screw fixation, a common challenge in orthopedic procedures. Its innovative devices are manufactured from biopolymers, which increase surface area contact between the bone and screws, distribute load transfer to facilitate bone healing and remodeling, and promote bone ingrowth for improved fixation. By leveraging biotextile technology, Woven Orthopedic Technologies aims to provide effective solutions for orthopedic surgeons, ultimately making advanced treatments more accessible and efficient for patients. The company is dedicated to tailoring orthopedic solutions to meet individual patient needs while ensuring that these technologies remain widely available.

MicroGEM is a microbiology research company focused on democratizing molecular biology by transferring complex molecular biology techniques from specialized laboratories to non-laboratory environments. The company employs an innovative enzymatic method for nucleic acid extraction, which facilitates sample preparation compatible with PCR (polymerase chain reaction) analysis. This technology supports the development of portable diagnostic devices aimed at managing infectious diseases and enhancing personalized medicine applications, making advanced molecular biology accessible to a broader audience.

LiveMetric is a medical device company focused on developing non-invasive sensing and deep data analytics solutions aimed at transforming the management of hypertension and cardiovascular diseases. The company has created a wearable, cuff-free device for blood pressure monitoring, which has received FDA clearance and is validated for accuracy against traditional arterial line measurements. This device offers continuous monitoring of vital signs, enabling healthcare providers to deliver AI-augmented care and treatment management. LiveMetric aims to empower patients, payors, and healthcare professionals with accurate, personalized data, facilitating better decision-making and improving the overall quality of care for individuals suffering from chronic cardiovascular conditions. By providing detailed daily activity mapping and real-time feedback, the company seeks to enhance the lives of millions worldwide affected by these health issues.

SymPhysis Medical focuses on developing innovative medical technologies aimed at treating chronic diseases, with an emphasis on enhancing patient experience and quality of life. The company's flagship product, releaze, addresses malignant pleural effusion (MPE), a common complication in late-stage cancer patients that can lead to severe shortness of breath and chest pain. This therapeutic device is designed for home use, effectively draining excess fluid from the pleural space. By utilizing an active component that enhances fluid removal efficiency, releaze alleviates distressing symptoms and improves treatment accessibility for patients requiring indwelling pleural catheter (IPC) therapies.

DermaSensor, Inc. is a Miami-based company that develops a handheld device designed to evaluate skin lesions for cancer using artificial intelligence and spectroscopy. Founded in 2009, the company's flagship product enables both physicians and consumers to conduct skin checks conveniently in clinical settings and at home. The device employs elastic scattering spectroscopy and machine learning algorithms to rapidly assess skin lesions, helping to identify potential cancerous cells. By providing an affordable and efficient tool for early detection, DermaSensor aims to improve access to skin cancer evaluations, addressing the significant number of Americans who have never undergone such checks. The technology not only facilitates immediate assessments but also alerts users when cancerous cells are detected, streamlining the process of skin cancer diagnostics.

ConKay Medical Systems is an early-stage medical device company focused on developing innovative solutions to address valvular regurgitation in patients suffering from progressive heart failure. The company's technology is centered around annular repair, which targets the primary cause of functional regurgitation while preserving the integrity of healthy leaflets. This approach aims to enhance the effectiveness of cardiovascular care, providing healthcare professionals with advanced tools to better manage this condition.

Garwood Medical Devices, LLC is a Buffalo, New York-based company that specializes in developing and manufacturing medical devices focused on infection management, particularly related to prosthetic implants and wound healing. The company's flagship product, BioPrax, is a minimally invasive device designed to target and eliminate biofilm infections on prosthetic knee implants during early intervention procedures. This innovative approach allows medical practitioners to effectively treat implant infections without the need for follow-up surgeries, thereby enabling patients to retain their implants. Founded in 2014 and initially known as Enermed, LLC, the company adopted its current name in December 2015, reflecting its commitment to advancing medical technology in infection control.

TrackX Technology specializes in developing advanced imaging guidance systems that enhance the safety and effectiveness of minimally invasive spine procedures. The company's technology offers real-time tracking of surgical instruments and implants, utilizing pseudo-live fluoroscopy to ensure precise positioning while significantly reducing radiation exposure for patients and medical staff. By focusing on procedurally driven imaging solutions, TrackX aims to improve surgical outcomes and operational efficiency within the operating room.

MeaCor Inc., based in Montreal, Canada, specializes in the development of innovative transcatheter devices designed to address heart disease, particularly valvular conditions. The company manufactures a catheter-based medical device aimed at repairing the mitral and tricuspid valves, utilizing an anchoring catheter system to facilitate these procedures. This technology focuses on transcatheter interventions that minimize the risks and trauma typically associated with conventional surgical methods. By doing so, MeaCor enables effective treatment for patients who are not candidates for traditional surgery, specifically targeting those suffering from mitral valve regurgitation.

Gravitas Medical, founded in 2015 and based in San Francisco, California, focuses on developing a personalized automated nutrition management system tailored for hospital settings. The company's innovative nasogastric feeding system evaluates patient readiness for feeding and enhances the delivery of nutrition. By optimizing these processes, Gravitas Medical aims to improve patient health outcomes, decrease overall healthcare costs, and alleviate the workload of nursing staff.

Endiatx, Inc. is a medical device manufacturing company based in Redwood City, California, specializing in innovative pill-sized robots designed for remote diagnostics and treatment within the gastrointestinal (GI) tract. Founded in 2019, the company has developed the Endiatx Pill Surgeon and the Endiatx Pill Robot, both of which feature advanced propulsion systems that allow them to navigate the entire length of the GI tract in about 30 minutes. These devices provide real-time video control, enabling physicians to perform sedation-free endoscopies in challenging areas, thus enhancing diagnostic capabilities and patient comfort.